Literature DB >> 24268837

Association between irritable bowel syndrome and colorectal cancer: a nationwide population-based study.

Cheng-Wen Hsiao1, Wen-Yen Huang2, Tao-Wei Ke3, Chih-Hsin Muo4, William Tzu-Liang Chen3, Fung-Chang Sung5, Chia-Hung Kao6.   

Abstract

OBJECTIVES: To determine whether irritable bowel syndrome (IBS) is associated with an increased risk for the subsequent colorectal cancer (CRC).
METHODS: We identified 91,746 patients who were diagnosed with IBS between 2000 and 2010 from the Taiwan National Health Insurance Research Database (NHIRD) as the study cohort, and randomly extracted the data of 183,492 patients matched by sex, age, and baseline year for the comparison cohort. The follow-up period was terminated after CRC development, withdrawal from the national health insurance (NHI) system, or at the end of 2010. Cumulative incidences and hazard ratios (HRs) of CRC development were determined.
RESULTS: During the first 2years of follow-up, the subsequent CRC incidence rates in the IBS and comparison cohorts were 37.3 and 5.61 per 10,000person-years, respectively (adjusted HR, 6.72; 95% CI, 5.70-7.92; p<.0001). Thereafter, the risk did not differ significantly between the 2 cohorts (adjusted HR, 1.08; 95% CI, 0.93-1.26); the participants in the IBS cohort commonly underwent more colonoscopies/sigmoidoscopies than did the non-IBS cohort.
CONCLUSIONS: IBS was not associated with the long-term development of CRC in Taiwan. The increased risk of CRC in the first 2years may have occurred because some CRC patients were initially misclassified as IBS patients.
Copyright © 2013 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cohort study; Colorectal cancer; Irritable bowel syndrome

Mesh:

Year:  2013        PMID: 24268837     DOI: 10.1016/j.ejim.2013.11.005

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  10 in total

Review 1.  Inflammation in irritable bowel syndrome: Myth or new treatment target?

Authors:  Emanuele Sinagra; Giancarlo Pompei; Giovanni Tomasello; Francesco Cappello; Gaetano Cristian Morreale; Georgios Amvrosiadis; Francesca Rossi; Attilio Ignazio Lo Monte; Aroldo Gabriele Rizzo; Dario Raimondo
Journal:  World J Gastroenterol       Date:  2016-02-21       Impact factor: 5.742

Review 2.  Common Functional Gastroenterological Disorders Associated With Abdominal Pain.

Authors:  Adil E Bharucha; Subhankar Chakraborty; Christopher D Sletten
Journal:  Mayo Clin Proc       Date:  2016-08       Impact factor: 7.616

3.  Overexpression of CPS1 is an independent negative prognosticator in rectal cancers receiving concurrent chemoradiotherapy.

Authors:  Yi-Ying Lee; Chien-Feng Li; Ching-Yih Lin; Sung-Wei Lee; Ming-Jen Sheu; Li-Ching Lin; Tzu-Ju Chen; Ting-Feng Wu; Chung-Hsi Hsing
Journal:  Tumour Biol       Date:  2014-08-07

4.  Diagnostic yield of endoscopy in irritable bowel syndrome: A nationwide prevalence study 1987-2016.

Authors:  Kyle Staller; Ola Olén; Jonas Söderling; Bjorn Roelstraete; Hans Törnblom; Hamed Khalili; Mingyang Song; Jonas F Ludvigsson
Journal:  Eur J Intern Med       Date:  2021-08-20       Impact factor: 4.487

5.  Overexpression of Transcobalamin 1 is an Independent Negative Prognosticator in Rectal Cancers Receiving Concurrent Chemoradiotherapy.

Authors:  Yi-Ying Lee; Yu-Ching Wei; Yu-Feng Tian; Ding-Ping Sun; Ming-Jen Sheu; Ching-Chieh Yang; Li-Ching Lin; Chen-Yi Lin; Chung-Hsi Hsing; Wan-Shan Li; Chien-Feng Li; Pei-Ling Hsieh; Ching-Yih Lin
Journal:  J Cancer       Date:  2017-05-12       Impact factor: 4.207

6.  Evidence-based clinical practice guidelines for irritable bowel syndrome 2020.

Authors:  Shin Fukudo; Toshikatsu Okumura; Masahiko Inamori; Yusuke Okuyama; Motoyori Kanazawa; Takeshi Kamiya; Ken Sato; Akiko Shiotani; Yuji Naito; Yoshiko Fujikawa; Ryota Hokari; Tastuhiro Masaoka; Kazuma Fujimoto; Hiroshi Kaneko; Akira Torii; Kei Matsueda; Hiroto Miwa; Nobuyuki Enomoto; Tooru Shimosegawa; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2021-02-04       Impact factor: 7.527

7.  A Network Pharmacology-Based Study on Irritable Bowel Syndrome Prevention and Treatment Utilizing Shenling Baizhu Powder.

Authors:  Meng Meng; Chen Bai; Bo Wan; Luqing Zhao; Zhe Li; Danyan Li; Shengsheng Zhang
Journal:  Biomed Res Int       Date:  2021-11-23       Impact factor: 3.411

8.  Risk of Colorectal Cancer in Patients With Irritable Bowel Syndrome: A Meta-Analysis of Population-Based Observational Studies.

Authors:  Xinhui Wu; Jingxi Wang; Zhen Ye; Jin Wang; Xibei Liao; Mengsi Liv; Zhen Svn
Journal:  Front Med (Lausanne)       Date:  2022-03-02

9.  Irritable brain caused by irritable bowel? A nationwide analysis for irritable bowel syndrome and risk of bipolar disorder.

Authors:  Chia-Jen Liu; Li-Yu Hu; Chiu-Mei Yeh; Yu-Wen Hu; Pan-Ming Chen; Tzeng-Ji Chen; Ti Lu
Journal:  PLoS One       Date:  2015-03-13       Impact factor: 3.240

Review 10.  Irritable Bowel Syndrome between Molecular Approach and Clinical Expertise-Searching for Gap Fillers in the Oxidative Stress Way of Thinking.

Authors:  Ioana-Miruna Balmus; Ovidiu Ilie-Dumitru; Alin Ciobica; Roxana-Oana Cojocariu; Carol Stanciu; Anca Trifan; Mirela Cimpeanu; Cristian Cimpeanu; Lucian Gorgan
Journal:  Medicina (Kaunas)       Date:  2020-01-19       Impact factor: 2.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.